ORBIMED ADVISORS LLC
Q4 2023 13F-HR Holdings
Net value change ($000)
+299,679
(6.4%)
New positions
14
Sold out positions
25
Turnover %
11.7%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q3 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| LLY | 113,093 | 113.2% |
| RayzeBio, Inc. | 88,816 | 152.5% |
| EWTX | 75,895 | 90.9% |
| BIIB | 71,055 | 49.7% |
| ELV | 66,726 | NEW |
| Gracell Biotechnologies Inc. | 66,651 | 248.6% |
| SRRK | 65,366 | 452.7% |
| ALXO | 32,304 | 234.4% |
| Third Harmonic Bio, Inc. | 26,468 | 71.7% |
| SpringWorks Therapeutics, Inc. | 25,753 | 28.1% |
Top Reduces (Value $000, Stocks/ETFs)
| HUM | -116,320 | -69.8% |
| Mirati Therapeutics, Inc. | -85,336 | -100.0% |
| BAX | -84,534 | -100.0% |
| CI | -66,225 | -100.0% |
| APLM | -59,120 | -87.7% |
| ABBV | -49,190 | -100.0% |
| MDGL | -36,993 | -100.0% |
| Horizon Therapeutics Public Ltd Co | -30,820 | -100.0% |
| CRNX | -26,804 | -31.1% |
| ACELYRIN, Inc. | -24,315 | -44.9% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
14,395
(0.3% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|